Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

What Was Tested

The trial (phase 4) is built around Semaglutide.

It had two arms (groups): Interventional Group (active comparator) and Control Group (active comparator).

Subjects receive all four chronic kidney disease therapies (medications) at the same time.

Subjects received standard of care.

The registry classes the interventions as drug.

More on the Plan

In current clinical practice, these medicines are usually started one at a time over many months.

This study will test a different approach, where these therapies are started in a structured and closely monitored way over a short period of time.

Participants will be randomly assigned to either a rapid initiation strategy or usual care.

In the rapid group, up to four approved therapies will be started and adjusted over approximately 8 weeks using a structured treatment plan.

Who Took Part

64 planned participants were the target.

It was open to people of any sex aged from 18 years up to 84 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Patients aged 18-84 years. Diagnosis of T2D. Eligible for all 4 drugs. Systolic BP (SBP) \>90 mmHg. Those willing to provide written informed consent and to adhere to study visits.

The full record lists 8 inclusion and 16 exclusion criteria; among the exclusions: type 1 diabetes; any known primary non-diabetic kidney disease (i.e., polycystic kidney disease, glomerulonephritis, interstitial nephritis, etc.); history of kidney transplant.

How the Study Was Run

Design: randomized, parallel-group and open-label.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Nothing was hidden in this open-label Semaglutide study: the participants and staff both knew the treatment.

It started in 2026-04-08 with completion listed for 2029-03-31.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: On-study retention rate at 6 months (time frame: 6 months). Change in UACR (time frame: 6 months).

It also tracked 15 secondary outcomes, for example Enrollment rate, Protocol adherence, Treatment discontinuation, Moderate Hyperkalemia, Severe Hyperkalemia and Acute Kidney Injury.

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Semaglutide in 64 people.

Its status is enrolling by invitation; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.